Joby's 'Prospectus' Isn't a Dilution Alarm — It's the Blade Earnout Cashing In

When a stock is down 52% year to date and files a prospectus, the default read in the market is always the same: more shares, more dilution, more pain. Joby Aviation dropped an SEC prospectus supplement on September 10, and on a ticker that has already fallen from a $19.98 high to the low-$6 range, that headline sounds like one more tap from the capital markets. Look inside the filing, though, and it is the opposite of a cash raise. Joby is selling nothing and receiving nothing.

The supplement registers the resale of 2,419,801 shares of Joby common stock. Those shares were not newly issued to raise cash; they were already handed to a selling stockholder — Strata Critical Medical, Inc., the entity formerly known as Blade Air Mobility — as earnout consideration in Joby's acquisition of Blade's passenger business. The filing exists only to give that seller registration rights to sell what it already owns. Joby states plainly that it "will not receive any proceeds" from the sale.

Scale is the first thing that should deflate any dilution panic. At the $6.42 last sale price in the prospectus, 2.4 million shares is worth roughly $15.5 million — against a market capitalization near $6.2 billion and a share count of roughly one billion, that is about a quarter of one percent of the company. Even if every registered share hit the market tomorrow, it would be a rounding error next to the roughly 31 million shares that changed hands on a single ordinary day.

The trigger behind those shares is the more interesting part. They were issued because the acquired operations achieved certain EBITDA milestones during the 12 months following the close of the Blade purchase. In plain terms, the passenger business Joby bought is hitting the profit targets the deal was structured around — on schedule. Earnout shares only vest when the seller delivers the numbers the price tag was based on.

That matters because Blade is not a sideshow anymore; it is nearly all of Joby's actual revenue. In the second quarter of 2026 alone the unit generated $36.2 million in revenue with seats sold up more than 50% year over year, and Joby raised its full-year revenue guidance to $115–125 million. The same business that is quietly cashing in its earnout is the business producing the only real growth the company has to show. A prospectus that looks like a distress signal is, at the margin, evidence the acquisition that feeds the income statement is working.

None of this means Joby has stopped being a capital-hungry pre-profit story — and this is where the honest math has to separate the two questions. The September filing is not dilution, but the absence of dilution in this filing says nothing about dilution risk elsewhere. The company burned roughly $743 million in free cash flow over the trailing year to fund certification and the commercialization ramp, which is why it raised about $1 billion in January through a convertible note and common stock combination and keeps an at-the-market facility on file. Today it carries net cash of more than $1.5 billion against its convertible debt, so it is not in immediate trouble — but the meter is still running at a pace that demands future financing.

So read the filing correctly. Joby did not tap new capital on September 10, and the pocket of stock it put up for resale is trivial against the float. The arguably bullish detail buried inside the legalese is that Blade's sellers only get paid their earnout by clearing EBITDA hurdles — and they just cleared one. The real question for anyone holding or watching this stock was never this prospectus; it is whether the recurring capital raises and the burn convert into a certified, scale product before the roughly $1.5 billion cushion runs down. That is the number to watch, not the 2.4 million resale shares.